{"disease":{"id":"mpgn","name":"mpgn"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05067127","title":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05755386","title":"Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06786338","title":"A Study of SGB-9768 in Patients with Complement-mediated Kidney Diseases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Suzhou Sanegene Bio Inc.","has_results":false},{"nct_id":"NCT07522099","title":"Chinese Adults With Kidney Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"ADARx Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03459443","title":"A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":22,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05383547","title":"Bortezomib for Treating Glomerular Diseases","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT03723512","title":"Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT04729062","title":"C3G/Primary IC-MPGN EAP","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}